Updated June 11, 2013
Salix Pharmaceuticals' (NASDAQ:SLXP) constipation drug Relistor, which failed to win regulatory approval last year, will be up for review by a FDA advisory committee.
May 22, 2013
Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.
Updated May 10, 2013
First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.
Updated May 10, 2013
The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.
Updated March 6, 2013
Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.
Updated February 15, 2013
Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.
January 3, 2013
Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.
January 2, 2013
Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.
November 8, 2012
Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;
Updated October 23, 2012
Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.
Salix backs "HE" documentary
September 5, 2012
The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.
August 9, 2012
The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.
August 9, 2012
Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.
Updated July 31, 2012
Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.
July 30, 2012
Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.
May 8, 2012
Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.
May 1, 2012
Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.
April 26, 2012
An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.
March 13, 2012
Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.
February 28, 2012
After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.